Chardan Capital Markets will host a Leadership Call with HighTide Therapeutics. The call will be moderated by Michael Morabito, PhD, Senior Research Analyst.

HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes. HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk fac

Approvals Support Clinical Trials in China and Canada for HTD1801 in Primary Sclerosing Cholangitis

SHENZHEN, CHINA and ROCKVILLE, MD, October 10, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801...

HighTide Therapeutics (“HighTide”) and Silexon Tech (“Silexon”) jointly announced a long-term strategic collaboration agreement in new drug research and development.

Based on Safety Data Review, DMC Recommends Continuing Trial